KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EPS (Basic) (2016 - 2025)

NovoCure (NVCR) has disclosed EPS (Basic) for 12 consecutive years, with -$0.22 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 63.93% to -$0.22 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.22 through Dec 2025, up 21.79% year-over-year, with the annual reading at -$1.22 for FY2025, 21.79% up from the prior year.
  • EPS (Basic) hit -$0.22 in Q4 2025 for NovoCure, up from -$0.33 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.04 in Q1 2021 to a low of -$0.61 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$0.31 across 5 years, with a median of -$0.31 in 2024.
  • Biggest five-year swings in EPS (Basic): plummeted 1150.0% in 2023 and later skyrocketed 63.93% in 2025.
  • Year by year, EPS (Basic) stood at -$0.25 in 2021, then plummeted by 44.0% to -$0.36 in 2022, then dropped by 22.22% to -$0.44 in 2023, then tumbled by 38.64% to -$0.61 in 2024, then skyrocketed by 63.93% to -$0.22 in 2025.
  • Business Quant data shows EPS (Basic) for NVCR at -$0.22 in Q4 2025, -$0.33 in Q3 2025, and -$0.36 in Q2 2025.